OptiNose Competitors, Revenue, Alternatives and Pricing
Estimated Revenue & Financials
- OptiNose's estimated annual revenue is currently $7.1M per year.
- OptiNose received $100.0M in venture funding in January 2018.
- OptiNose's estimated revenue per employee is $33,014
- OptiNose's total funding is $401.4M.
- OptiNose has 214 Employees.
- OptiNose grew their employee count by -1% last year.
- OptiNose currently has 1 job openings.
What Is OptiNose?
OptiNose, Inc., established in 2010 and headquartered in Yardley, Pennsylvania, is a publicly traded, global specialty pharmaceutical company focused on serving the needs of patients cared for by ENT and Allergy specialists. Our team of kind, passionate, innovative people is building a new kind of organization without the encumbrances of a company with legacy systems and beliefs. We are unified by a shared mission: to improve lives. We do this while also creating great value for the healthcare system and great outcomes for our stakeholders. As innovators in every aspect of our work, we pursue faster and less costly product development, explore evolving commercial business models, and actively seek innovative ways to be more effective and efficient in all areas of the business. We operate with an overarching commitment to doing what is right. We are committed to working together as a team that chooses to live every day by core Company values that guide our daily behaviors, creating a foundation for future success. These include Friendship, Possibility Thinking, Fearless Conversations, Openness, Authenticity, Perseverance, and One Mission. We have a proven record of successful product development, a promising pipeline of new products, and a team of highly motivated and highly accomplished professionals working from offices in the U.S., U.K., and Norway. The Company's first products are based on patented Optinose Exhalation Delivery Systems. This technology is a platform for developing novel treatments that create meaningful new clinical benefits by enabling high and deep intranasal deposition of carefully selected medications. Optinose successfully developed its first product in the neurology therapeutic area (ONZETRA® Xsail®) and licensed North American commercialization rights to Avanir (subsequently acquired by Otsuka). In September 2017, Optinose received FDA approval for its second product, XHANCE(TM). XHANCE is an innovative product that delivers a topical steroid high and deep into nasal passages where inflammation can cause chronic symptoms. XHANCE is currently indicated for the treatment of nasal polyps in adults, and in 2018 we plan to initiate clinical trials in pursuit of a follow-on indication for chronic sinusitis, an indication for which we believe no other drugs are approved anywhere in the world. We are actively expanding our team to support this exciting product, including in commercial, supply chain, compliance, quality assurance, medical affairs, clinical research and other areas necessary for a rapidly growing fully integrated specialty pharmaceutical company. Beyond XHANCE, Optinose is evaluating pipeline opportunities that target large markets with significant unmet patient needs. These include opportunities in the ENT and allergy therapeutic areas and select nose-to-brain applications in the central nervous system therapeutic area (such as OPN-21 for narcolepsy and OPN-300 for autism and Prader-Willi syndrome). We have a near-term plan, a long-term vision, and a strong team to guide us. Keep an eye on us as we move forward to meet the needs of today's - and tomorrow's - healthcare challenges.keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals